2 Stocks That Are Just Getting Started: Tallgrass Energy, LP (TGE), Cigna Corporation (CI)

    The shares of Tallgrass Energy, LP (NYSE:TGE) has been pegged with a rating of Neutral by Piper Jaffray in its latest research note that was published on July 17th, 2019. The research company has also assigned a $24 price target. Piper Jaffray wasn’t the only research firm that published a report of Tallgrass Energy, LP, with other equities research analysts also giving their opinion on the stock. Goldman advised investors in its research note published on April 3rd, 2019, to Neutral the TGE stock while also putting a $26 price target. The stock had earned Neutral rating from Credit Suisse when it published its report on February 21st, 2019. That day the Credit Suisse set price target on the stock to $25. The stock was given Underperform rating by BofA/Merrill in its report released on January 11th, 2019, the day when the price target on the stock was placed at $22. Credit Suisse was of a view that TGE is Outperform in its latest report on October 11th, 2018. Goldman thinks that TGE is worth Buy rating. This was contained in the firm’s report on October 9th, 2018.

    The consensus currently stands at a Hold while its average price target is $20.82. The price of the stock the last time has raised by 36.48% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 61.97.

    The shares of the company added by 0.41% during the trading session on Thursday, reaching a low of $19.44 while ending the day at $19.49. During the trading session, a total of 2.51 million shares were traded which represents a -27.97% decline from the average session volume which is 1.96M shares. TGE had ended its last session trading at 19.41. Tallgrass Energy, LP currently has a market cap of $5.42B, while its P/E ratio stands at 13.35, while its P/E earnings growth sits at 6.54, with a beta of 0.64. Tallgrass Energy, LP debt-to-equity ratio currently stands at 1.84, while its quick ratio hovers at 0.60. TGE 52-week low price stands at $14.28 while its 52-week high price is $25.96.

    Investment analysts at Bernstein published a research note on August 6th, 2019 where it informed investors and clients that Cigna Corporation (NYSE:CI) is now rated as Outperform. Their price target on the stock stands at $205. Goldman also rated CI as Downgrade on April 3rd, 2019, with its price target of $27 suggesting that CI could surge by 28.95% from its current share price. Even though the stock has been trading at $154.99/share, analysts expect it to surge higher by -1.32% to reach $215.25/share. It started the day trading at $157.58 and traded between $152.54 and $152.94 throughout the trading session.

    A look at its technical shows that CI’s 50-day SMA is 163.93 while its 200-day SMA stands at 173.64. The stock has a high of $226.60 for the year while the low is $141.95. The company’s P/E ratio currently sits at 13.99, while the P/B ratio is 1.32. At the moment, only of Cigna Corporation shares were sold short. The company’s average trading volume currently stands at 1.92M shares, which means that the short-interest ratio is just 3.06 days. Over the past seven days, the company moved, with its shift of 4.56%. Looking further, the stock has dropped -0.57% over the past 90 days while it lost -7.26% over the last six months.

    The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more CI shares, increasing its portfolio by +0.53% during the last quarter. This move now sees The Vanguard Group Inc purchasing 149,521 shares in the last quarter, thus it now holds 28,165,642 shares of CI, with a total valuation of $4,785,905,889. T Rowe Price Associates Inc meanwhile sold more CI shares in the recently filed quarter, changing its stake to $4,747,345,263 worth of shares. Capital Research Management Co followed the path by increasing its CI portfolio by +0.03% in the quarter. This means that Capital Research Management Co bought 5,984 shares in the last quarter and now controls 20,194,649 shares of the CI stock, with the valuation hitting $3,431,474,758.

    Similarly, BlackRock Fund Advisors decreased its Cigna Corporation shares by -7.26% during the recently filed quarter. After selling -1,274,616 shares in the last quarter, the firm now controls 16,289,510 shares of Cigna Corporation which are valued at $2,767,913,539. In the same vein, Dodge Cox increased its Cigna Corporation shares by during the most recent reported quarter. The firm bought 2,954,197 shares during the quarter which increased its stakes to 16,203,850 shares and is now valued at $2,753,358,192. Following these latest developments, around 0.20% of Cigna Corporation stocks are owned by institutional investors and hedge funds.